Last update 21 Nov 2024

[203Pb]VMT01

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals
Synonyms-
Target
MC1R
Mechanism
MC1R modulators(Melanocortin receptor 1 modulators), SPECT(Single-photon emission-computed tomography enhancers)
Therapeutic Areas
NeoplasmsSkin and Musculoskeletal Diseases
Active Indication
Melanoma, Cutaneous MalignantMetastatic melanomaMucosal Melanoma+ [1]
Inactive Indication
Uveal Melanoma
Originator Organization
Viewpoint Molecular Targeting, Inc.Viewpoint Molecular Targeting, Inc.
Active Organization
Perspective Therapeutics, Inc.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

2
Clinical Trials associated with [203Pb]VMT01
NCT05655312 / RecruitingPhase 1/2
A Phase I/IIa, First-In-Human, Multi-Center, Monotherapy and Combination-Therapy With Nivolumab, Dose-Escalation and Dose-Expansion Study of [212Pb]VMT01 Melanocortin-1 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Subjects With Previously Treated Unresectable or Metastatic Melanoma
NCT04904120 / CompletedPhase 1
A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma
100 Clinical Results associated with [203Pb]VMT01
Login to view more data
100 Translational Medicine associated with [203Pb]VMT01
Login to view more data
100 Patents (Medical) associated with [203Pb]VMT01
Login to view more data
100 Deals associated with [203Pb]VMT01
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uveal MelanomaPhase 3
US
Perspective Therapeutics, Inc.
05 Mar 2021
Melanoma, Cutaneous MalignantPhase 2
US
Perspective Therapeutics, Inc.
01 Jun 2023
Metastatic melanomaPhase 2
US
Perspective Therapeutics, Inc.
01 Jun 2023
Mucosal MelanomaPhase 2
US
Perspective Therapeutics, Inc.
01 Jun 2023
Unresectable MelanomaPhase 2
US
Perspective Therapeutics, Inc.
01 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free